Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar 9;3(3):e002254.
doi: 10.1136/bmjopen-2012-002254.

Assessment of a multimarker strategy for prediction of mortality in older heart failure patients: a cohort study

Affiliations

Assessment of a multimarker strategy for prediction of mortality in older heart failure patients: a cohort study

Christian Bjurman et al. BMJ Open. .

Abstract

Objective: Primarily to develop a multimarker score for prediction of 3-year mortality in older patients with decompensated heart failure (HF).

Design: Prospective cohort study.

Setting: Secondary care. Single centre. PATIENTS AND BIOMARKERS: 131 patients, aged ≥65 years, with decompensated HF were included. Assessment of biomarkers was performed at discharge.

Primary outcome measure: 3-year mortality.

Results: Mean age was 73±11 years; mean left ventricular ejection fraction , 43±14%; 53% were male. The 3-year mortality was 53.4%. The following N-terminal brain natriuretic peptide (NTproBNP) levels could optimally stratify mortality: <2000 ng/l (n=39), 30.8% mortality; 2000-8000 ng/l (n=58), 51.7% mortality; and >8000 ng/l (n=34), 82.4% mortality. However, in the 2000-8000 ng/l range, NTproBNP levels had low-prognostic capacity, based on the area under the receiver operating characteristic curve (AUC=0.53; 95% CI 0.40 to 0.67). In this group, multivariate analysis identified age, cystatin C (CysC), and troponin T (TnT) levels as independent risk factors. A risk score based on these three risk factors separated a high-risk and low-risk groups within the NTproBNP range of 2000-8000 ng/l. The score exhibited a significantly higher AUC (0.75; 95% CI 0.62 to 0.86) than NTproBNP alone (p=0.03) in this NTproBNP group and had similar prognostic capacity as NTproBNP in patients below or above this NTproBNP range (p=0.57). Net reclassification improvement and integrated discriminatory improvement in the group with NTproBNP levels between 2000 and 8000 ng/l was 54% and 23%, respectively, and in the whole cohort 22% and 11%, respectively.

Conclusions: Our results suggested that, to assess risk in HF, older patients required significantly higher levels of NTproBNP than younger patients. Furthermore, a risk score that included TnT and CysC at discharge, and age could improve risk stratification for mortality in older patients with HF in particular when NTproBNP was moderately elevated.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier plots show the relationship between 3-year mortality and significant variables (age, troponin T, TnT, and cystatin C, CysC) identified in multivariate analysis (and N-terminal brain natriuretic peptide, NTproBNP) (A–D). p Values for comparisons between strata are shown in table 3.
Figure 2
Figure 2
Kaplan-Meier plot shows the relationship between 3-year mortality and the composite risk factor score (p<0.0001 for linear trend).
Figure 3
Figure 3
Distribution of the prognostic score among patients who died (right of 0) and survived (left of 0) within 3 years of inclusion in the study.

References

    1. Askoxylakis V, Thieke C, Pleger ST, et al. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer 2010;10:105. - PMC - PubMed
    1. Hoyert DL, Heron MP, Murphy SL, et al. Deaths: final data for 2003. Natl Vital Stat Rep 2006;54:1–120 - PubMed
    1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2012 update: a report from the American heart association. Circulation 2012;125:188–97 - PubMed
    1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global Burden of disease study. Lancet 1997;349:1269–76 - PubMed
    1. Mogensen UM, Ersboll M, Andersen M, et al. Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups. Eur J Heart Fail 2011;13:1216–23 - PubMed

LinkOut - more resources